Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05978648 | Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy(SMA-BC-002) | recruiting | Phase 2 | 116 | wang shusenOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03269981 | Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer | active not recruiting | N/A | 827 | Samsung Medical CenterOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05451784 | Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS(TILS001) | recruiting | Phase 1 / Phase 2 | 20 | Fundacio Clinic BarcelonaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06144346 | Metastases Directed Therapy for Oligometastatic Breast Cancer | recruiting | N/A | 150 | National Cancer Institute, EgyptOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06140576 | The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. | not yet recruiting | Phase 1 / Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT06093022 | Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study(SurMed-BCLM) | recruiting | — | 720 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121557 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121570 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06110845 | CLinical Evaluation Of a comPuter Algorithm To Report BreAst cAncers (CLEOPATRAA)(CLEOPATRAA) | not yet recruiting | — | 800 | The Leeds Teaching Hospitals NHS TrustOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06104085 | 99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT03561454 | A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients | active not recruiting | — | 100 | MedStar Franklin Square Medical CenterOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT06090747 | Improving Lifestyle Behavior by "Joven, Fuerte y Saludable" Multidisciplinary Program. | recruiting | N/A | 146 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT04925856 | Immunomonitoring of Breast Cancer Patients During Systemic Treatment(IMMUNE CAPTURE) | recruiting | N/A | 150 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04172259 | ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | active not recruiting | Phase 2 | 156 | Sun Yat-sen UniversityOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT04687956 | Primary Surgical Prevention of Breast Cancer-related Lymphedema(LYMPHA) | recruiting | N/A | 72 | Gangnam Severance HospitalOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06076772 | Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients | not yet recruiting | — | 54 | Assiut UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06073418 | Dietary Habits, Nutritional Knowledge and Physical Activity Assessment in Early Stage Breast Cancer Patients(DEMETRA) | recruiting | — | 1,098 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03324932 | Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer | active not recruiting | Phase 3 | 160 | Kyoto Prefectural University of MedicineOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05569811 | NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial(VALENTINE) | active not recruiting | Phase 2 | 120 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06035016 | Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer | recruiting | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06023277 | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 40 | Jacinto Convit World Organization Inc.OTHER | 2 | Sep 5, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06015113 | Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis | not yet recruiting | N/A | 20 | Xi'an International Medical Center HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06000917 | A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer | recruiting | Phase 2 | 62 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05983094 | Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | not yet recruiting | Phase 2 | 181 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05980208 | A Real-world Study of Inetetamab for First-line Treatment of MBC | not yet recruiting | — | 150 | Hunan Cancer HospitalOTHER | 0 | Aug 8, 2023 | clinicaltrials |
| NCT05981001 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 170 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05981014 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 196 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05976412 | Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer | recruiting | N/A | 1,355 | Ruijin HospitalOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05979220 | Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy | not yet recruiting | Phase 2 | 178 | Shuangyue LiuOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00909909 | Radiation Therapy in Treating Women With Early Stage Breast Cancer | active not recruiting | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04722692 | Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ(SENTINOT_2) | recruiting | Phase 3 | 500 | Uppsala UniversityOTHER | 3 | Aug 3, 2023 | clinicaltrials |
| NCT05975437 | Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer(NABOR) | enrolling by invitation | — | 1,040 | Comprehensive Cancer Centre The NetherlandsOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05862610 | The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC | not yet recruiting | Phase 2 | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05955521 | Exosome as the Prognostic and Predictive Biomarker in EBC Patients | active not recruiting | N/A | 200 | Samsung Medical CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT01357772 | Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up(TAM-01) | active not recruiting | Phase 3 | 500 | Andrea DeCensiOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05430399 | Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer | recruiting | Phase 3 | 349 | Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05928429 | Effects of Cryotherapy on Taxane-Induced Neuropathy in Patients With Breast Cancer | recruiting | N/A | 300 | Maria LendorfOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05824325 | Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY） | active not recruiting | Phase 1 / Phase 2 | 56 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05916755 | Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform(PORTRAIT) | recruiting | — | 100 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05058183 | Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer(Safe-De) | recruiting | N/A | 400 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05904964 | Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) | recruiting | Phase 3 | 288 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04020575 | Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) | recruiting | Phase 1 | 69 | Minerva Biotechnologies CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05901025 | Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients | not yet recruiting | — | 5,000 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 13, 2023 | clinicaltrials |
| NCT04642508 | The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction(PreQ-20) | active not recruiting | N/A | 81 | University Hospital A CoruñaOTHER | 1 | Jun 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 30, 2023source: clinicaltrials